Long-term study for geographic atrophy treatment
Part of Eyes & vision clinical trials.
This study is for people who already took part in a previous trial for geographic atrophy (a late stage of dry age-related macular degeneration) and received the study drug or a sham. It looks at the long-term safety of the treatment over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were in a parent study for JNJ-81201887 (AAVCAGsCD59) or a sham treatment for geographic atrophy.
- You understand the study's purpose and agree to its procedures by signing a consent form.
- You do not need to use birth control while taking part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This trial tests a new nerve stimulation treatment for people with geographic atrophy, a form of advanced dry age-related macular degeneration. It aims to see if this treatment can help preserve or improve vision.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This study tests a new gene therapy that may slow or stop the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes vision loss. The treatment is given as an injection into the eye and aims to preserve remaining vision.
This trial tests an investigational treatment called PST-611 for geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. It aims to see if the treatment is safe and may slow the progression of the disease.
Hear when a new Geographic Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.